Patient‐reported outcomes for NAFLD/NASH: rational for expanded use

Abstract

It is estimated that one in four adults around the world has non‐alcoholic fatty liver disease (NAFLD), a condition that can lead to non‐alcoholic steatohepatitis (NASH), serious liver damage and, ultimately, death. The arrival of new treatment options and prevention strategies for NAFLD/NASH will result in an increasing number of clinical trials targeting this disease. Younossi outlined (1) the increasing importance of including patient‐reported outcomes (PROs) in future clinical trials for NAFLD/NASH treatment. We fully agree and wish to underline additional points that deserve consideration when dealing with PROs and NAFLD/NASH.

This article is protected by copyright. All rights reserved.

https://ift.tt/2BwN929